A Hepatitis C Virus-Associated Cirrhotic Patient Developing Interstitial Pneumonia during the Course of Antiviral Therapy with Ombitasvir/Paritaprevir/Ritonavir
Oral direct-acting antivirals (DAAs) are the main therapy for hepatitis C virus (HCV)-associated liver disease in Japan. Daclatasvir/asunaprevir is the first agent and sofosbuvir/ledipasvir is the secondary agent for HCV genotype 1b. More recently, ombitasvir/paritaprevir/ritonavir is also recommend...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2017-06-01
|
Series: | Case Reports in Gastroenterology |
Subjects: | |
Online Access: | http://prod.karger.com/Article/FullText/462965 |
_version_ | 1818854352505274368 |
---|---|
author | Kazuo Tarao Kouzo Yamada |
author_facet | Kazuo Tarao Kouzo Yamada |
author_sort | Kazuo Tarao |
collection | DOAJ |
description | Oral direct-acting antivirals (DAAs) are the main therapy for hepatitis C virus (HCV)-associated liver disease in Japan. Daclatasvir/asunaprevir is the first agent and sofosbuvir/ledipasvir is the secondary agent for HCV genotype 1b. More recently, ombitasvir/paritaprevir/ritonavir is also recommended as a potent therapy for HCV genotype 1b. Among the adverse events associated with these oral DAAs, interstitial pneumonia is one of the most severe ones. Regarding treatment with daclatasvir plus asunaprevir or sofosbuvir plus ledipasvir, a few cases have already been reported in a postmarketing surveillance. Recently, we have encountered a HCV-associated genotype 1b cirrhosis patient who developed interstitial pneumonia during treatment with ombitasvir/paritaprevir/ritonavir and who recovered after drug discontinuation without corticosteroid therapy. Interstitial pneumonia was confirmed by chest x-ray and chest computed tomography. The serum KL-6 level was elevated to 1,180 U/mL. The total duration of the drug administration was 7 weeks, and she achieved SVR24. This is the first detailed report in the literature on the development of interstitial pneumonia during treatment with ombitasvir/paritaprevir/ritonavir. When dry cough appeared in the treatment with DAAs, chest computed tomography and the evaluation of serum KL-6 level were recommended. |
first_indexed | 2024-12-19T07:51:21Z |
format | Article |
id | doaj.art-0c99429b362d466ba24a6264ddc7a3b8 |
institution | Directory Open Access Journal |
issn | 1662-0631 |
language | English |
last_indexed | 2024-12-19T07:51:21Z |
publishDate | 2017-06-01 |
publisher | Karger Publishers |
record_format | Article |
series | Case Reports in Gastroenterology |
spelling | doaj.art-0c99429b362d466ba24a6264ddc7a3b82022-12-21T20:30:08ZengKarger PublishersCase Reports in Gastroenterology1662-06312017-06-0111236937610.1159/000462965462965A Hepatitis C Virus-Associated Cirrhotic Patient Developing Interstitial Pneumonia during the Course of Antiviral Therapy with Ombitasvir/Paritaprevir/RitonavirKazuo TaraoKouzo YamadaOral direct-acting antivirals (DAAs) are the main therapy for hepatitis C virus (HCV)-associated liver disease in Japan. Daclatasvir/asunaprevir is the first agent and sofosbuvir/ledipasvir is the secondary agent for HCV genotype 1b. More recently, ombitasvir/paritaprevir/ritonavir is also recommended as a potent therapy for HCV genotype 1b. Among the adverse events associated with these oral DAAs, interstitial pneumonia is one of the most severe ones. Regarding treatment with daclatasvir plus asunaprevir or sofosbuvir plus ledipasvir, a few cases have already been reported in a postmarketing surveillance. Recently, we have encountered a HCV-associated genotype 1b cirrhosis patient who developed interstitial pneumonia during treatment with ombitasvir/paritaprevir/ritonavir and who recovered after drug discontinuation without corticosteroid therapy. Interstitial pneumonia was confirmed by chest x-ray and chest computed tomography. The serum KL-6 level was elevated to 1,180 U/mL. The total duration of the drug administration was 7 weeks, and she achieved SVR24. This is the first detailed report in the literature on the development of interstitial pneumonia during treatment with ombitasvir/paritaprevir/ritonavir. When dry cough appeared in the treatment with DAAs, chest computed tomography and the evaluation of serum KL-6 level were recommended.http://prod.karger.com/Article/FullText/462965Interstitial pneumoniaDirect-acting antiviralsDry coughHepatitis C virus liver diseaseOmbitasvir/paritaprevir/ritonavir |
spellingShingle | Kazuo Tarao Kouzo Yamada A Hepatitis C Virus-Associated Cirrhotic Patient Developing Interstitial Pneumonia during the Course of Antiviral Therapy with Ombitasvir/Paritaprevir/Ritonavir Case Reports in Gastroenterology Interstitial pneumonia Direct-acting antivirals Dry cough Hepatitis C virus liver disease Ombitasvir/paritaprevir/ritonavir |
title | A Hepatitis C Virus-Associated Cirrhotic Patient Developing Interstitial Pneumonia during the Course of Antiviral Therapy with Ombitasvir/Paritaprevir/Ritonavir |
title_full | A Hepatitis C Virus-Associated Cirrhotic Patient Developing Interstitial Pneumonia during the Course of Antiviral Therapy with Ombitasvir/Paritaprevir/Ritonavir |
title_fullStr | A Hepatitis C Virus-Associated Cirrhotic Patient Developing Interstitial Pneumonia during the Course of Antiviral Therapy with Ombitasvir/Paritaprevir/Ritonavir |
title_full_unstemmed | A Hepatitis C Virus-Associated Cirrhotic Patient Developing Interstitial Pneumonia during the Course of Antiviral Therapy with Ombitasvir/Paritaprevir/Ritonavir |
title_short | A Hepatitis C Virus-Associated Cirrhotic Patient Developing Interstitial Pneumonia during the Course of Antiviral Therapy with Ombitasvir/Paritaprevir/Ritonavir |
title_sort | hepatitis c virus associated cirrhotic patient developing interstitial pneumonia during the course of antiviral therapy with ombitasvir paritaprevir ritonavir |
topic | Interstitial pneumonia Direct-acting antivirals Dry cough Hepatitis C virus liver disease Ombitasvir/paritaprevir/ritonavir |
url | http://prod.karger.com/Article/FullText/462965 |
work_keys_str_mv | AT kazuotarao ahepatitiscvirusassociatedcirrhoticpatientdevelopinginterstitialpneumoniaduringthecourseofantiviraltherapywithombitasvirparitaprevirritonavir AT kouzoyamada ahepatitiscvirusassociatedcirrhoticpatientdevelopinginterstitialpneumoniaduringthecourseofantiviraltherapywithombitasvirparitaprevirritonavir AT kazuotarao hepatitiscvirusassociatedcirrhoticpatientdevelopinginterstitialpneumoniaduringthecourseofantiviraltherapywithombitasvirparitaprevirritonavir AT kouzoyamada hepatitiscvirusassociatedcirrhoticpatientdevelopinginterstitialpneumoniaduringthecourseofantiviraltherapywithombitasvirparitaprevirritonavir |